Pharma Stock to Watch After Company Announces ₹271 Cr Acquisition of Innovcare

Synopsis: Sun Pharmaceutical Industries Limited shares are in focus as it plans to acquire 100% of Innovcare Lifesciences Private, a Mumbai-based pharma marketing and distribution company, in an all-cash deal worth ₹271.2 crore, strengthening its consumer healthcare reach.

The shares of the Large-Cap company, which specialises in the development, manufacturing, and marketing of speciality pharmaceuticals, branded generics, complex formulations, and Active Pharmaceutical Ingredients (APIs), are in focus as set for a big move to acquire Innovcare to strengthen its product portfolio in the healthcare and pharmaceutical space.

With a market capitalization of Rs. 4,43,866.51 crores in the day’s trade, the shares of Sun Pharmaceutical Industries Ltd rose 0.8 percent, making a high of Rs. 1,853.55 per share compared to its previous closing price of Rs. 1,837.15 per share.

What Happened 

Sun Pharmaceutical Industries Limited has announced that it will acquire 100% of the outstanding shares of Innovcare Lifesciences Private Limited, a Mumbai-based pharmaceutical marketing and distribution company. The transaction is part of Sun Pharma’s ongoing strategy to strengthen its product portfolio in the healthcare and pharmaceutical space.

Innovcare Lifesciences operates in the marketing, distribution, and sale of pharmaceutical drugs as well as nutraceutical and cosmeceutical products. The company reported a revenue of Rs. 94.06 crore in FY 2025–26, showing steady growth over the past three years. Its turnover was Rs. 86.09 crore in FY 2024–25 and Rs. 80.93 crore in FY 2023–24, indicating consistent expansion in its operations within India.

The deal is structured as an all-cash transaction, with Sun Pharma agreeing to pay approximately Rs. 271.2 crore for the acquisition. The company confirmed that the acquisition is not a related-party transaction, and neither the promoter group nor related entities have any interest in Innovcare. No regulatory approvals are required for completion of the deal.

The acquisition is expected to be completed on or before 31 July 2026. Once completed, it will give Sun Pharma full ownership and control over Innovcare, helping it expand its reach in distribution channels and strengthen its presence in consumer healthcare and speciality product segments.

Financials & Others

The company’s revenue rose by 12.76 percent from Rs. 12,959 crores in March 2025 to Rs. 14,612 crores in March 2026. Meanwhile, Net profit rose from Rs. 2,154 crores to Rs. 2,710 crores in the same period.

The company shows strong profitability with a ROCE of 20.5% and ROE of 16.0%, indicating efficient use of both capital employed and shareholders’ equity. These levels suggest the business is generating solid returns from its investments and is operating in a financially productive manner.

Its debt-to-equity ratio of 0.06 reflects a very conservative capital structure with minimal reliance on debt, reducing financial risk. Along with a healthy dividend payout of 34.1%, it indicates a balanced approach of rewarding shareholders while maintaining financial stability and retaining sufficient earnings for growth.

In FY25, the company reported over $6.2B+ in revenue and maintained a strong balance sheet with $3.1B+ in cash. About 20% of its revenue came from the fast-growing Innovative Medicines business, reflecting its focus on higher-value segments. It is also the #1 pharmaceutical company in India by revenue, with a presence across 100+ countries, highlighting its global scale and diversified operations.

Sun Pharmaceutical Industries Ltd is one of India’s largest pharmaceutical companies and a major global player in generic medicines and speciality pharmaceuticals. Founded in 1983 and headquartered in Mumbai, it develops, manufactures, and sells a wide range of formulations and active pharmaceutical ingredients used in treatments across multiple therapeutic areas such as cardiology, neurology, dermatology, and oncology.

The company operates in more than 100 countries, supplying affordable generic drugs as well as branded formulations through its global network. It has expanded significantly through acquisitions and R&D investments, building a strong presence in regulated markets like the US and Europe. 

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post Pharma Stock to Watch After Company Announces ₹271 Cr Acquisition of Innovcare appeared first on Trade Brains.